Loading…

Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?

Unprovoked venous thromboembolism (uVTE) may be the first manifestation of cancer. The main objectives of this study were to compare limited screening (LS) and extended screening (ES) and to make a protocol to approach these patients. This is a retrospective, unicentric observational study that incl...

Full description

Saved in:
Bibliographic Details
Published in:Curēus (Palo Alto, CA) CA), 2020-02, Vol.12 (2), p.e6934-e6934
Main Authors: Ferreira, Filipa, Pereira, José, Lynce, Ana, Nunes Marques, José, Martins, Ana
Format: Article
Language:English
Subjects:
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c339t-b93f9692c51a832bf78f94b81f7f6fbb72fd33c4fdafef71d858a5d0e12418d43
cites
container_end_page e6934
container_issue 2
container_start_page e6934
container_title Curēus (Palo Alto, CA)
container_volume 12
creator Ferreira, Filipa
Pereira, José
Lynce, Ana
Nunes Marques, José
Martins, Ana
description Unprovoked venous thromboembolism (uVTE) may be the first manifestation of cancer. The main objectives of this study were to compare limited screening (LS) and extended screening (ES) and to make a protocol to approach these patients. This is a retrospective, unicentric observational study that included 245 patients with venous thromboembolism (VTE) admitted to an Internal Medicine Service for five years. The incidence of cancer and mortality during hospitalization, and at one and three years after admission were calculated in both LS and ES groups and compared. Of the 245 patients with VTE, 59 (24.1%) had uVTE: 35 (59.3%) were submitted to LS and 24 (40.7%) to ES, with 10 (4.1%) diagnosis of cancer. In the following three years, 10 more patients were diagnosed. There were no statistically significant differences in inpatient diagnosis rates (8.6% vs. 4.2%; p=0.51) or in-hospital mortality (2.9% vs. 4.2%; p=0.79) or mortality at one year (8.6% vs. 8.3%; p=0.97) and three years (20.0% vs. 20.8%; p = 0.94) between LS and ES groups respectively. The Computerized Registry of Patients with Venous Thromboembolism (RIETE) score was equal or superior to 3 in 69.5% (N=41) of the population with uVTE. The results of our study are consistent with the literature; there are no differences between screenings, as the difference in the number of diagnoses does not reflect on mortality. There were no statistically significant differences between the two types of screening in this population. We suggest a protocol that includes the RIETE score to better select the patients who might benefit the most from an ES.
doi_str_mv 10.7759/cureus.6934
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7011576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2368381297</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-b93f9692c51a832bf78f94b81f7f6fbb72fd33c4fdafef71d858a5d0e12418d43</originalsourceid><addsrcrecordid>eNpdkU1LHTEUhkOxVLGuupdAN0K5mo-ZSeJCqRetBcFClW6EkElOvLEzyTWZueK_d-RasS4OOZCHl_fwIPSFkn0hanVgxwxj2W8Urz6gLUYbOZNUVhtv9k20U8odIYQSwYggn9AmZ6SmktRb6GZuooWMf9sMEEO8xSHiX2YIEIeCH8KwwNdxmdMq_QWHrxY59W2CabpQ-kN8nh7wkLBLOAzYRIf_LBI-gQg-DOX4M_roTVdg5-XdRtdnp1fz89nF5Y-f8-8XM8u5Gmat4l41itmaGslZ64X0qmol9cI3vm0F845zW3lnPHhBnaylqR0ByioqXcW30dE6dzm2PTg7dc-m08scepMfdTJB__8Tw0LfppUWhNJaNFPA3ktATvcjlEH3oVjoOhMhjUUzXleCN1KoCf36Dr1LY47TeRPVSC4pU2Kivq0pm1MpGfxrGUr0szi9FqefxU307tv-r-w_TfwJW9aV3g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2368381297</pqid></control><display><type>article</type><title>Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?</title><source>Publicly Available Content (ProQuest)</source><source>PubMed Central</source><creator>Ferreira, Filipa ; Pereira, José ; Lynce, Ana ; Nunes Marques, José ; Martins, Ana</creator><creatorcontrib>Ferreira, Filipa ; Pereira, José ; Lynce, Ana ; Nunes Marques, José ; Martins, Ana</creatorcontrib><description>Unprovoked venous thromboembolism (uVTE) may be the first manifestation of cancer. The main objectives of this study were to compare limited screening (LS) and extended screening (ES) and to make a protocol to approach these patients. This is a retrospective, unicentric observational study that included 245 patients with venous thromboembolism (VTE) admitted to an Internal Medicine Service for five years. The incidence of cancer and mortality during hospitalization, and at one and three years after admission were calculated in both LS and ES groups and compared. Of the 245 patients with VTE, 59 (24.1%) had uVTE: 35 (59.3%) were submitted to LS and 24 (40.7%) to ES, with 10 (4.1%) diagnosis of cancer. In the following three years, 10 more patients were diagnosed. There were no statistically significant differences in inpatient diagnosis rates (8.6% vs. 4.2%; p=0.51) or in-hospital mortality (2.9% vs. 4.2%; p=0.79) or mortality at one year (8.6% vs. 8.3%; p=0.97) and three years (20.0% vs. 20.8%; p = 0.94) between LS and ES groups respectively. The Computerized Registry of Patients with Venous Thromboembolism (RIETE) score was equal or superior to 3 in 69.5% (N=41) of the population with uVTE. The results of our study are consistent with the literature; there are no differences between screenings, as the difference in the number of diagnoses does not reflect on mortality. There were no statistically significant differences between the two types of screening in this population. We suggest a protocol that includes the RIETE score to better select the patients who might benefit the most from an ES.</description><identifier>ISSN: 2168-8184</identifier><identifier>EISSN: 2168-8184</identifier><identifier>DOI: 10.7759/cureus.6934</identifier><identifier>PMID: 32051805</identifier><language>eng</language><publisher>United States: Cureus Inc</publisher><subject>Anticoagulants ; Blood tests ; Cancer ; Diabetes ; Embolisms ; Gender ; Hospitals ; Hypertension ; Internal Medicine ; Lung diseases ; Medical diagnosis ; Medical screening ; Miscellaneous ; Mortality ; NMR ; Nuclear magnetic resonance ; Oncology ; Patients ; Surgery ; Thromboembolism ; Thrombosis ; Tumors ; Ultrasonic imaging ; Variables ; Veins &amp; arteries ; Womens health</subject><ispartof>Curēus (Palo Alto, CA), 2020-02, Vol.12 (2), p.e6934-e6934</ispartof><rights>Copyright © 2020, Ferreira et al.</rights><rights>Copyright © 2020, Ferreira et al. This work is published under http://creativecommons.org/licenses/by/3.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2020, Ferreira et al. 2020 Ferreira et al.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-b93f9692c51a832bf78f94b81f7f6fbb72fd33c4fdafef71d858a5d0e12418d43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2368381297/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2368381297?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32051805$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ferreira, Filipa</creatorcontrib><creatorcontrib>Pereira, José</creatorcontrib><creatorcontrib>Lynce, Ana</creatorcontrib><creatorcontrib>Nunes Marques, José</creatorcontrib><creatorcontrib>Martins, Ana</creatorcontrib><title>Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?</title><title>Curēus (Palo Alto, CA)</title><addtitle>Cureus</addtitle><description>Unprovoked venous thromboembolism (uVTE) may be the first manifestation of cancer. The main objectives of this study were to compare limited screening (LS) and extended screening (ES) and to make a protocol to approach these patients. This is a retrospective, unicentric observational study that included 245 patients with venous thromboembolism (VTE) admitted to an Internal Medicine Service for five years. The incidence of cancer and mortality during hospitalization, and at one and three years after admission were calculated in both LS and ES groups and compared. Of the 245 patients with VTE, 59 (24.1%) had uVTE: 35 (59.3%) were submitted to LS and 24 (40.7%) to ES, with 10 (4.1%) diagnosis of cancer. In the following three years, 10 more patients were diagnosed. There were no statistically significant differences in inpatient diagnosis rates (8.6% vs. 4.2%; p=0.51) or in-hospital mortality (2.9% vs. 4.2%; p=0.79) or mortality at one year (8.6% vs. 8.3%; p=0.97) and three years (20.0% vs. 20.8%; p = 0.94) between LS and ES groups respectively. The Computerized Registry of Patients with Venous Thromboembolism (RIETE) score was equal or superior to 3 in 69.5% (N=41) of the population with uVTE. The results of our study are consistent with the literature; there are no differences between screenings, as the difference in the number of diagnoses does not reflect on mortality. There were no statistically significant differences between the two types of screening in this population. We suggest a protocol that includes the RIETE score to better select the patients who might benefit the most from an ES.</description><subject>Anticoagulants</subject><subject>Blood tests</subject><subject>Cancer</subject><subject>Diabetes</subject><subject>Embolisms</subject><subject>Gender</subject><subject>Hospitals</subject><subject>Hypertension</subject><subject>Internal Medicine</subject><subject>Lung diseases</subject><subject>Medical diagnosis</subject><subject>Medical screening</subject><subject>Miscellaneous</subject><subject>Mortality</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Oncology</subject><subject>Patients</subject><subject>Surgery</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>Variables</subject><subject>Veins &amp; arteries</subject><subject>Womens health</subject><issn>2168-8184</issn><issn>2168-8184</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkU1LHTEUhkOxVLGuupdAN0K5mo-ZSeJCqRetBcFClW6EkElOvLEzyTWZueK_d-RasS4OOZCHl_fwIPSFkn0hanVgxwxj2W8Urz6gLUYbOZNUVhtv9k20U8odIYQSwYggn9AmZ6SmktRb6GZuooWMf9sMEEO8xSHiX2YIEIeCH8KwwNdxmdMq_QWHrxY59W2CabpQ-kN8nh7wkLBLOAzYRIf_LBI-gQg-DOX4M_roTVdg5-XdRtdnp1fz89nF5Y-f8-8XM8u5Gmat4l41itmaGslZ64X0qmol9cI3vm0F845zW3lnPHhBnaylqR0ByioqXcW30dE6dzm2PTg7dc-m08scepMfdTJB__8Tw0LfppUWhNJaNFPA3ktATvcjlEH3oVjoOhMhjUUzXleCN1KoCf36Dr1LY47TeRPVSC4pU2Kivq0pm1MpGfxrGUr0szi9FqefxU307tv-r-w_TfwJW9aV3g</recordid><startdate>20200210</startdate><enddate>20200210</enddate><creator>Ferreira, Filipa</creator><creator>Pereira, José</creator><creator>Lynce, Ana</creator><creator>Nunes Marques, José</creator><creator>Martins, Ana</creator><general>Cureus Inc</general><general>Cureus</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200210</creationdate><title>Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?</title><author>Ferreira, Filipa ; Pereira, José ; Lynce, Ana ; Nunes Marques, José ; Martins, Ana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-b93f9692c51a832bf78f94b81f7f6fbb72fd33c4fdafef71d858a5d0e12418d43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Anticoagulants</topic><topic>Blood tests</topic><topic>Cancer</topic><topic>Diabetes</topic><topic>Embolisms</topic><topic>Gender</topic><topic>Hospitals</topic><topic>Hypertension</topic><topic>Internal Medicine</topic><topic>Lung diseases</topic><topic>Medical diagnosis</topic><topic>Medical screening</topic><topic>Miscellaneous</topic><topic>Mortality</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Oncology</topic><topic>Patients</topic><topic>Surgery</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>Variables</topic><topic>Veins &amp; arteries</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ferreira, Filipa</creatorcontrib><creatorcontrib>Pereira, José</creatorcontrib><creatorcontrib>Lynce, Ana</creatorcontrib><creatorcontrib>Nunes Marques, José</creatorcontrib><creatorcontrib>Martins, Ana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content (ProQuest)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Curēus (Palo Alto, CA)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ferreira, Filipa</au><au>Pereira, José</au><au>Lynce, Ana</au><au>Nunes Marques, José</au><au>Martins, Ana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?</atitle><jtitle>Curēus (Palo Alto, CA)</jtitle><addtitle>Cureus</addtitle><date>2020-02-10</date><risdate>2020</risdate><volume>12</volume><issue>2</issue><spage>e6934</spage><epage>e6934</epage><pages>e6934-e6934</pages><issn>2168-8184</issn><eissn>2168-8184</eissn><abstract>Unprovoked venous thromboembolism (uVTE) may be the first manifestation of cancer. The main objectives of this study were to compare limited screening (LS) and extended screening (ES) and to make a protocol to approach these patients. This is a retrospective, unicentric observational study that included 245 patients with venous thromboembolism (VTE) admitted to an Internal Medicine Service for five years. The incidence of cancer and mortality during hospitalization, and at one and three years after admission were calculated in both LS and ES groups and compared. Of the 245 patients with VTE, 59 (24.1%) had uVTE: 35 (59.3%) were submitted to LS and 24 (40.7%) to ES, with 10 (4.1%) diagnosis of cancer. In the following three years, 10 more patients were diagnosed. There were no statistically significant differences in inpatient diagnosis rates (8.6% vs. 4.2%; p=0.51) or in-hospital mortality (2.9% vs. 4.2%; p=0.79) or mortality at one year (8.6% vs. 8.3%; p=0.97) and three years (20.0% vs. 20.8%; p = 0.94) between LS and ES groups respectively. The Computerized Registry of Patients with Venous Thromboembolism (RIETE) score was equal or superior to 3 in 69.5% (N=41) of the population with uVTE. The results of our study are consistent with the literature; there are no differences between screenings, as the difference in the number of diagnoses does not reflect on mortality. There were no statistically significant differences between the two types of screening in this population. We suggest a protocol that includes the RIETE score to better select the patients who might benefit the most from an ES.</abstract><cop>United States</cop><pub>Cureus Inc</pub><pmid>32051805</pmid><doi>10.7759/cureus.6934</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2168-8184
ispartof Curēus (Palo Alto, CA), 2020-02, Vol.12 (2), p.e6934-e6934
issn 2168-8184
2168-8184
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7011576
source Publicly Available Content (ProQuest); PubMed Central
subjects Anticoagulants
Blood tests
Cancer
Diabetes
Embolisms
Gender
Hospitals
Hypertension
Internal Medicine
Lung diseases
Medical diagnosis
Medical screening
Miscellaneous
Mortality
NMR
Nuclear magnetic resonance
Oncology
Patients
Surgery
Thromboembolism
Thrombosis
Tumors
Ultrasonic imaging
Variables
Veins & arteries
Womens health
title Cancer Screening in Patients with Unprovoked Thromboembolism: How to do it and Who Benefits?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T14%3A28%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cancer%20Screening%20in%20Patients%20with%20Unprovoked%20Thromboembolism:%20How%20to%20do%20it%20and%20Who%20Benefits?&rft.jtitle=Cur%C4%93us%20(Palo%20Alto,%20CA)&rft.au=Ferreira,%20Filipa&rft.date=2020-02-10&rft.volume=12&rft.issue=2&rft.spage=e6934&rft.epage=e6934&rft.pages=e6934-e6934&rft.issn=2168-8184&rft.eissn=2168-8184&rft_id=info:doi/10.7759/cureus.6934&rft_dat=%3Cproquest_pubme%3E2368381297%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c339t-b93f9692c51a832bf78f94b81f7f6fbb72fd33c4fdafef71d858a5d0e12418d43%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2368381297&rft_id=info:pmid/32051805&rfr_iscdi=true